| 1 |
Zhu K, Ding X, Chen Z, Xi Q, Pang X, Chen W, Miao L. Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn's disease. Front Pharmacol 2023;14:1096816. [PMID: 36726584 DOI: 10.3389/fphar.2023.1096816] [Reference Citation Analysis]
|
| 2 |
. 克罗恩病患儿英夫利西单抗维持治疗前血药浓度与疾病转归的关系. Zhongguo Dang Dai Er Ke Za Zhi 2022;24. [PMID: 36398551 DOI: 10.7499/j.issn.1008-8830.2205181] [Reference Citation Analysis]
|
| 3 |
Lodhia N, Rao S. Updates in therapeutic drug monitoring in inflammatory bowel disease. World J Gastroenterol 2022; 28(21): 2282-2290 [DOI: 10.3748/wjg.v28.i21.2282] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 4 |
Xie W, Xiao S, Huang H, Zhang Z. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis. Front Immunol 2022;13:847160. [PMID: 35300336 DOI: 10.3389/fimmu.2022.847160] [Reference Citation Analysis]
|
| 5 |
Con D, van Langenberg DR, Vasudevan A. Deep learning vs conventional learning algorithms for clinical prediction in Crohn's disease: A proof-of-concept study. World J Gastroenterol 2021; 27(38): 6476-6488 [PMID: 34720536 DOI: 10.3748/wjg.v27.i38.6476] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV Jr, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:2014-25. [PMID: 34388143 DOI: 10.14309/ajg.0000000000001396] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 7 |
Mattoo VY, Basnayake C, Connell WR, Ding N, Kamm MA, Lust M, Niewiadomski O, Thompson A, Wright EK. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. Aliment Pharmacol Ther 2021;54:249-66. [PMID: 34153124 DOI: 10.1111/apt.16479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Paul S, Williet N, Nancey S, Veyrard P, Boschetti G, Phelip JM, Flourie B, Roblin X. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification. Dig Dis Sci 2021;66:2744-9. [PMID: 32936345 DOI: 10.1007/s10620-020-06567-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Con D, Parthasarathy N, Bishara M, Luber RP, Joshi N, Wan A, Rickard JA, Long T, Connoley DJ, Sparrow MP, Gibson PR, van Langenberg DR, Vasudevan A. Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's Disease. J Crohns Colitis 2021;15:583-93. [PMID: 32949458 DOI: 10.1093/ecco-jcc/jjaa194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Lund K, Larsen MD, Knudsen T, Kjeldsen J, Nielsen RG, Mertz Nørgård B. Infliximab, Immunomodulators and Treatment Failures in Paediatric and Adolescent Patients with Crohn's Disease: a Nationwide Cohort Study. J Crohns Colitis 2021;15:575-82. [PMID: 32926166 DOI: 10.1093/ecco-jcc/jjaa188] [Reference Citation Analysis]
|
| 11 |
Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors? Am J Clin Dermatol 2021;22:139-47. [PMID: 33398848 DOI: 10.1007/s40257-020-00579-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 12 |
Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 13 |
Nakase H, Matsumoto T, Watanabe K, Hisamatsu T. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. J Gastroenterol 2020;55:824-32. [PMID: 32661927 DOI: 10.1007/s00535-020-01702-x] [Reference Citation Analysis]
|
| 14 |
Santacana Juncosa E, Rodríguez-Alonso L, Padullés Zamora A, Guardiola J, Rodríguez-Moranta F, Serra Nilsson K, Bas Minguet J, Morandeira Rego F, Colom Codina H, Padullés Zamora N. Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy. Br J Clin Pharmacol 2021;87:494-505. [PMID: 32495380 DOI: 10.1111/bcp.14410] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 15 |
Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [PMID: 31961001 DOI: 10.1111/apt.15643] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 16 |
Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG. Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. J Crohns Colitis 2019;13:1527-36. [PMID: 31094417 DOI: 10.1093/ecco-jcc/jjz103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 17 |
Park SH, Al-bawardy B, Aniwan S, Kane SV, Coelho-prabhu N, Papadakis KA, Kisiel JB, Bruining DH, Faubion WA, Raffals LE, Pardi DS, Tremaine WJ, Stephens MC, Tung J, Khanna S, Willrich MAV, Loftus EV. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019;1:otz047. [DOI: 10.1093/crocol/otz047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T. Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. JGH Open 2020;4:410-6. [PMID: 32514446 DOI: 10.1002/jgh3.12266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 19 |
Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, de Lourdes Setsuko Ayrizono M, Fagundes JJ, Leal RF. Authors' Reply - Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies? Clinics (Sao Paulo) 2019;74:e1517. [PMID: 31576921 DOI: 10.6061/clinics/2019/e1517] [Reference Citation Analysis]
|
| 20 |
Papamichael K, Juncadella A, Wong D, Rakowsky S, Sattler LA, Campbell JP, Vaughn BP, Cheifetz AS. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. J Crohns Colitis 2019;13:976-81. [PMID: 30689771 DOI: 10.1093/ecco-jcc/jjz018] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 20.8] [Reference Citation Analysis]
|
| 21 |
Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-1668.e3. [PMID: 30928454 DOI: 10.1016/j.cgh.2019.03.037] [Cited by in Crossref: 158] [Cited by in F6Publishing: 157] [Article Influence: 39.5] [Reference Citation Analysis]
|
| 22 |
Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, Scharl M, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflamm Bowel Dis 2019;25:1357-66. [PMID: 30776076 DOI: 10.1093/ibd/izz012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol 2019;35:302-10. [PMID: 30973355 DOI: 10.1097/MOG.0000000000000536] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 24 |
Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. Inflamm Bowel Dis 2019;25:1036-43. [PMID: 30335139 DOI: 10.1093/ibd/izy320] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 25 |
Seinen ML, De Boer NK, van Bodegraven AA. Key insights from therapeutic drug monitoring in Crohn's disease patients. Expert Opin Drug Metab Toxicol 2019;15:399-406. [PMID: 30892105 DOI: 10.1080/17425255.2019.1597054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 26 |
Gomes LEM, da Silva FAR, Pascoal LB, Ricci RL, Nogueira G, Camargo MG, Lourdes Setsuko Ayrizono M, Fagundes JJ, Leal RF. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease. Clinics (Sao Paulo) 2019;74:e824. [PMID: 30994711 DOI: 10.6061/clinics/2019/e824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Chen Y, Wang JC, Yang CM, Fan Q, Zheng J, Liu H. Positive acceleration adaptive training attenuates gastric ischemia-reperfusion injury through COX-2 and PGE2 expression. Exp Ther Med 2019;17:2901-6. [PMID: 30930978 DOI: 10.3892/etm.2019.7288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 28 |
Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:880-9. [PMID: 30784100 DOI: 10.1111/apt.15179] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 29 |
Mechie NC, Mavropoulou E, Ellenrieder V, Petzold G, Kunsch S, Neesse A, Amanzada A. Serum vitamin D but not zinc levels are associated with different disease activity status in patients with inflammatory bowel disease. Medicine (Baltimore) 2019;98:e15172. [PMID: 30985701 DOI: 10.1097/MD.0000000000015172] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 30 |
Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019;10:2040622319838443. [PMID: 30937157 DOI: 10.1177/2040622319838443] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 31 |
Verstockt B, Verstockt S, Creyns B, Tops S, Van Assche G, Gils A, Ceuppens JL, Vermeire S, Ferrante M, Breynaert C. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. Aliment Pharmacol Ther 2019;49:572-81. [PMID: 30663072 DOI: 10.1111/apt.15126] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 32 |
Nemoz B, Ternant D, Bailly S, Gautier-Veyret E, Jourdil JF, Bonaz B, Stanke-Labesque F. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. Br J Clin Pharmacol 2019;85:722-8. [PMID: 30575085 DOI: 10.1111/bcp.13845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 33 |
Juncadella A, Papamichael K, Vaughn BP, Cheifetz AS. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Dig Dis Sci 2018;63:3067-73. [PMID: 30006816 DOI: 10.1007/s10620-018-5202-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
|
| 34 |
Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. Inflamm Bowel Dis 2018;24:2266-71. [PMID: 29718327 DOI: 10.1093/ibd/izy132] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 35 |
Holmstrøm RB, Mogensen DV, Brynskov J, Ainsworth MA, Nersting J, Schmiegelow K, Steenholdt C. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease. Dig Dis Sci 2018;63:1583-91. [PMID: 29564674 DOI: 10.1007/s10620-018-5020-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 36 |
Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-Noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-Horin S. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study. Am J Gastroenterol 2018;113:890-8. [PMID: 29867175 DOI: 10.1038/s41395-018-0073-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 37 |
Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therap Adv Gastroenterol 2018;11:1756284818772786. [PMID: 29774052 DOI: 10.1177/1756284818772786] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 38 |
Yacoub W, Williet N, Pouillon L, Di-Bernado T, De Carvalho Bittencourt M, Nancey S, Lopez A, Paul S, Zallot C, Roblin X, Peyrin-Biroulet L. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Aliment Pharmacol Ther 2018;47:906-12. [PMID: 29384209 DOI: 10.1111/apt.14548] [Cited by in Crossref: 73] [Cited by in F6Publishing: 48] [Article Influence: 14.6] [Reference Citation Analysis]
|
| 39 |
Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin Immunol 2019;206:9-14. [PMID: 29545207 DOI: 10.1016/j.clim.2018.03.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 40 |
Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther 2018;47:478-84. [PMID: 29210094 DOI: 10.1111/apt.14458] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 10.4] [Reference Citation Analysis]
|
| 41 |
Bar-Yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-Horin S, Chowers Y, Ungar B. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther 2018;47:212-8. [PMID: 29124774 DOI: 10.1111/apt.14410] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 9.2] [Reference Citation Analysis]
|
| 42 |
Rentsch C, Headon B, Ward MG, Gibson PR. Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response? J Gastroenterol Hepatol 2018;33:10-1. [PMID: 29284080 DOI: 10.1111/jgh.14001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 43 |
Su HY, Ward MG, Sparrow MP. Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline. Transl Gastroenterol Hepatol 2017;2:113. [PMID: 29354770 DOI: 10.21037/tgh.2017.12.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 44 |
Park SH, Aniwan S, Loftus EV. Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease. Current Opinion in Pharmacology 2017;37:65-71. [DOI: 10.1016/j.coph.2017.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 45 |
Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther 2017;46:873-82. [PMID: 28884856 DOI: 10.1111/apt.14318] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 46 |
Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy. World J Gastroenterol 2017; 23(34): 6197-6200 [PMID: 28974885 DOI: 10.3748/wjg.v23.i34.6197] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 47 |
Ward MG, Irving PM. Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply. Aliment Pharmacol Ther 2017;46:465. [PMID: 28707788 DOI: 10.1111/apt.14209] [Reference Citation Analysis]
|
| 48 |
Seow CH, Panaccione R. Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Aliment Pharmacol Ther 2017;46:463-4. [PMID: 28707795 DOI: 10.1111/apt.14185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
